Shionogi Pharma Appoints Ray Russo as Vice President, Primary Care Business Unit

Shionogi Pharma Appoints Ray Russo as Vice President, Primary Care Business Unit

ATLANTA--(BUSINESS WIRE)--Jan 21, 2010 - Shionogi Pharma, Inc. today announced that Ray Russo has joined the Company as Vice President, Primary Care Business Unit, reporting to Joe Ciaffoni, Executive Vice President and Chief Commercial Officer. In his new position, Mr. Russo is responsible for setting the vision and strategy for the business; delivering top and bottom line results; inspiring and empowering the Primary Care team; and as part of the senior management team, working cross-functionally with key groups to ensure the long-term success of the Primary Care business unit's sales and operations.

Commenting on the announcement, Patrick Fourteau, President and Chief Executive Officer, said, "Ray comes to Shionogi Pharma with over 25 years of experience with Schering-Plough Corporation, where he most recently served as Global Vice President Marketing, Cardiovascular Franchise. He complements our team well with his wealth of leadership and pharmaceutical experience. We look forward to Ray's contributions to our continued success."

Mr. Russo earned a BA in Economics from Rutgers College. He holds an MBA, with an Accounting emphasis, from Rutgers University Graduate School of Business.

About Shionogi Pharma, Inc.

Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.) is a U.S.-based group company of Shionogi & Co., Ltd. Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Pharma, Inc. based in Atlanta, Georgia, please visit www.shionogipharma.com.

Contact: Shionogi Pharma, Inc.
Joseph T. Schepers, +1-678-341-1401
[email protected]

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.